Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Short Communication

Volume 12, Number 6, December 2021, pages 358-362

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients

Figure 1. Changes in eGFR (a) and serum uric acid (b) after the switching from fenofibrate to pemafibrate in type 2 diabetic patients. Black circles and error bars indicate mean and SD, respectively. *P < 0.05 vs. values at baseline. eGFR: estimated glomerular filtration rate; SD: standard deviation.

**Table 1.** Characteristics for Type 2 Diabetic Patients Who Had Undergone the Switching From Fenofibrate to Pemafibrate (n = 15
Characteristics
SD: standard deviation.
Clinical characteristics
Age (years)	55.1 ± 12.0
Gender (male/female)	8/7
Body weight (mean ± SD, kg)	75.2 ± 15.6
Body mass index (mean ± SD, kg/m²)	27.5 ± 4.8
Systolic blood pressure (mean ± SD, mm Hg)	133.4 ± 12.7
Diastolic blood pressure (mean ± SD, mm Hg)	79.4 ± 11.2
Treatments for type 2 diabetes
Dipeptidyl peptidase-4 inhibitors (n)	4
Metformin (n)	7
Sodium-glucose co-transporter 2 inhibitors (n)	8
Glucagon-like peptide 1 receptor agonists (n)	3
Sulfonylurea (n)	1
Insulin (n)	2
α-glucosidase inhibitors (n)	1
Treatments for hypertension
Angiotensin receptor blockers (n)	8
Calcium antagonists (n)	6
Diuretics (n)	2
β-blockers (n)	1
Mineralocorticoid receptor antagonist (n)	1
Treatments for dyslipidemia
Statins (n)	2
Ezetimibe (n)	6

Table 1. Characteristics for Type 2 Diabetic Patients Who Had Undergone the Switching From Fenofibrate to Pemafibrate (n = 15

Characteristics

SD: standard deviation.

Clinical characteristics

Age (years)

55.1 ± 12.0

Gender (male/female)

8/7

Body weight (mean ± SD, kg)

75.2 ± 15.6

Body mass index (mean ± SD, kg/m²)

27.5 ± 4.8

Systolic blood pressure (mean ± SD, mm Hg)

133.4 ± 12.7

Diastolic blood pressure (mean ± SD, mm Hg)

79.4 ± 11.2

Treatments for type 2 diabetes

Dipeptidyl peptidase-4 inhibitors (n)

Metformin (n)

Sodium-glucose co-transporter 2 inhibitors (n)

Glucagon-like peptide 1 receptor agonists (n)

Sulfonylurea (n)

Insulin (n)

α-glucosidase inhibitors (n)

Treatments for hypertension

Angiotensin receptor blockers (n)

Calcium antagonists (n)

Diuretics (n)

β-blockers (n)

Mineralocorticoid receptor antagonist (n)

Treatments for dyslipidemia

Statins (n)

Ezetimibe (n)

**Table 2.** Changes in Metabolic Parameters After Switching From Fenofibrate to Pemabibrate
	Baseline	After 3 months	After 6 months	After 12 months
*P < 0.05 vs. baseline.
Aspartate aminotransferase (IU/L)	79.1 ± 194.1	63.6 ± 148.4	34.4 ± 35.7	26.7 ± 8.5
Alanine aminotransferase (IU/L)	37.4 ± 31.1	31.1 ± 20.9	27.8 ± 18.6*	34.7 ± 27.1
γ-glutamyl transpeptidase (IU/L)	144.8 ± 319.8	83.4 ± 140.7	94.2 ± 160.9	92.0 ± 154.8
Creatine phosphokinase (IU/L)	100.1 ± 72.4	110.2 ± 64.2	100.6 ± 37.5	136.3 ± 139.5
Plasma glucose (mg/dL)	148.9 ± 42.9	164.6 ± 53.1	150.1 ± 34.4	162.5 ± 41.6
HbA1c (%)	7.0 ± 1.2	6.9 ± 0.9	6.8 ± 0.8	6.9 ± 0.8
Total cholesterol (mg/dL)	216.7 ± 70.3	201.4 ± 34.2	191.4 ± 15.4	186.1 ± 30.8
Triglyceride (mg/dL)	346.3 ± 468.5	314.3 ± 335.8	203.9 ± 105.4	217.5 ± 123.0
HDL-cholesterol (mg/dL)	55.5 ± 27.5	47.4 ± 10.1	47.8 ± 10.8	51.7 ± 11.9
LDL-cholesterol (mg/dL)	108.7 ± 18.5	112.0 ± 16.9	116.8 ± 15.4	108.4 ± 26.5
Non-HDL-cholesterol (mg/dL)	161.2 ± 72.9	154.0 ± 34.3	143.6 ± 10.7	134.4 ± 30.9

Table 2. Changes in Metabolic Parameters After Switching From Fenofibrate to Pemabibrate

Baseline

After 3 months

After 6 months

After 12 months

*P < 0.05 vs. baseline.

Aspartate aminotransferase (IU/L)

79.1 ± 194.1

63.6 ± 148.4

34.4 ± 35.7

26.7 ± 8.5

Alanine aminotransferase (IU/L)

37.4 ± 31.1

31.1 ± 20.9

27.8 ± 18.6*

34.7 ± 27.1

γ-glutamyl transpeptidase (IU/L)

144.8 ± 319.8

83.4 ± 140.7

94.2 ± 160.9

92.0 ± 154.8

Creatine phosphokinase (IU/L)

100.1 ± 72.4

110.2 ± 64.2

100.6 ± 37.5

136.3 ± 139.5

Plasma glucose (mg/dL)

148.9 ± 42.9

164.6 ± 53.1

150.1 ± 34.4

162.5 ± 41.6

HbA1c (%)

7.0 ± 1.2

6.9 ± 0.9

6.8 ± 0.8

6.9 ± 0.8

Total cholesterol (mg/dL)

216.7 ± 70.3

201.4 ± 34.2

191.4 ± 15.4

186.1 ± 30.8

Triglyceride (mg/dL)

346.3 ± 468.5

314.3 ± 335.8

203.9 ± 105.4

217.5 ± 123.0

HDL-cholesterol (mg/dL)

55.5 ± 27.5

47.4 ± 10.1

47.8 ± 10.8

51.7 ± 11.9

LDL-cholesterol (mg/dL)

108.7 ± 18.5

112.0 ± 16.9

116.8 ± 15.4

108.4 ± 26.5

Non-HDL-cholesterol (mg/dL)

161.2 ± 72.9

154.0 ± 34.3

143.6 ± 10.7

134.4 ± 30.9